- Anglicus
- Gallus
- Germanus
- Portuguese
- Spanish
- Russian
- Iaponica
- Coreanica
- Arabic
- Hibernica
- Graeculus
- Turkish
- Italiae
- DANICULUS
- Romanian
- Indonesiaca
- Bohemica
- Africikaans
- SCELIDUS
- POLICULO
- Basque
- Catalana
- Esperanto
- Hindi
- Lago
- Illyrica
- Amharicus
- Armeniana
- Azerbaieni
- Belarusian
- Bengalica
- BOSNIAN
- Bulgarica
- Cebuano
- Chichewa
- Corsican
- Crovatica
- Batavica
- Estonian
- Philippinica
- Fennica
- Frisian
- Gallaeca
- Georgian
- Gujarati
- Haitiaian
- Hausa
- HAWAIUS
- Hebraica
- Hmong
- Hungarian
- IMETIANICUS
- Igbo
- Javanese
- Cannada
- Kazakh
- Khmer
- Kurdica
- Kyrgyz
- Latine
- Latvian
- Lithuanian
- Lithuanian
- Macedonian
- MALAGASUS
- Malae
- Malayalam
- Melitensis
- Maorice
- Marathi
- Mongolica
- Burmese
- Nepalica
- Norwegian
- Pastua
- Persicus
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Moravica
- Carnica
- Somali
- Samoan
- Scoti Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ucraina
- Urdu
- Uzbek
- Vietnamica
- Cambrica
- Xhosa
- LOKINDIS
- Yoruba
- Zuluensis
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
SAGACITAS currus - T
Progressionem historia currus - T cellula therapy
Et progressionem de currus - T cellula justo potest reduced ad MCMLXXXIX, cum crucem G et tres alii scientists primum propositum conceptum "currus". Deinde, in MMVIII, in Fred Hutchison Cancer Institutum Primo Used Car T cellulis ut tractare b - cellula lymphoma, demonstrando salutem huius therapeuticam modum. In MMX, in primo prospere Case CD19 - targeting currus - T therapy ad b - cell - consociata non - Hodgkin lymphoma nuntiavit in Civitatibus Foederatis Americae. Deinde in MMXI, Professor Carl June scriptor studio ad University of Pennsylvania significans profectum, et Puella scriptor felix curatio fabulam, promptus currus T immune cellula est ingressus novum periodum CREPITUS. In MMXVII, in US cibo et medicamento administratione (FDA) probatus est ipsum LICENTIA primi currus T cellula productum Kymriah, quod notata est adventu de commercial era currus T cellulis. In eodem anno, YEGCARTA, secunda currus - T immune cellulam Lorem productum, quod etiam probatus ad ipsum LICENTIA. In MMXX, in FDA probatus a tertia currus T - cellula therapy productum Tecartus. In MMXXI, in FDA probatus duo currus - T immunotherapy products, Breyanzi et Abecma, ad curatio refractónem et relapsing magna b - cellula lymphoma et multiple myeloma, respectively. In eodem anno, Cde ex Sina quoque probatus ad ipsum LICENTIA duos currus T immune cellula Lorem products axi - Cel et Relma - Cel, tam ad curatio ad adulta aegris et refracty aut recurrentes magnam b - cellula lymphoma.
In MMXXII, in FDA probatus est ipsum LICENTIA de Carvykti, a car - T cellula therapy productum targeting c cellula maturatio antigen (BCMA) ad curatio referration vel refracty multiple myeloma.
In hoc puncto, currus T cellula illic ingressus in era Cancer Immunotherapy et aperuit a splendidis laude in hoc mundo.
Quid est car - T cellula Therapy
Car T cellula Therapy, etiam notum ut chimeric antigen receptor T c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c VIII (currus - t), est tumor immunotherapy quod utitur geneticae engineering ad modify T cellulis in vitro. Hoc concedit eos specie agnoscis tumore cellulis et injiciunt cellulis in patientes estote ad tractare morbum.
